Revolution Medicines (RVMD) Liabilities and Shareholders Equity (2019 - 2026)

Revolution Medicines has reported Liabilities and Shareholders Equity for 8 years, with the latest figure at $4.3 billion in Q2 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 77.94% year-over-year to $4.3 billion in Q2 2026; TTM through Jun 2026 was $11.2 billion, a 22.68% increase from a year earlier, with the FY2025 full-year figure at $2.4 billion, down 7.97% from the prior year.
• Liabilities and Shareholders Equity was $4.3 billion for Q2 2026 at Revolution Medicines, up from $2.3 billion in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $4.3 billion in Q2 2026, with the low at $632.8 million in Q2 2022.
• Average Liabilities and Shareholders Equity over 5 years is $1.8 billion, with a median of $1.9 billion recorded in 2024.
• The sharpest annual moves came in 2022 and 2023: Liabilities and Shareholders Equity retreated 18.25% in 2022, then jumped 153.93% in 2023.
• Over 5 years, Liabilities and Shareholders Equity stood at $811.9 million in 2022, then surged by 153.93% to $2.1 billion in 2023, then grew by 24.09% to $2.6 billion in 2024, then slipped by 7.97% to $2.4 billion in 2025, then jumped by 83.62% to $4.3 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $4.3 billion (Q2 2026), $2.3 billion (Q1 2026), and $2.4 billion (Q4 2025), per Business Quant data.